Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 257.46B +7.1% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 20.09 |
| Forward PE | 16.04 |
| Dividend | 9.80 (3.04%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 778,976 |
| Average Volume | 1,224,739 |
| Open | 322.00 |
| Previous Close | 320.70 |
| Day's Range | 317.40 - 323.50 |
| 52-Week Range | 231.90 - 374.90 |
| Beta | 0.21 |
| RSI | 30.66 |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases,... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche Enters $750 Mln Merger Deal To Acquire PathAI To Expand AI-Driven Diagnostics
(RTTNews) - Roche (RHHBY), a healthcare company, announced on Thursday that it has entered into a definitive merger agreement to acquire PathAI, a digital, AI-powered technology firm serving pathology...
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further miles...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered...
The Zacks Analyst Blog Highlights Microsoft, Bank of America, Roche and GSI Technology
Microsoft faces pressure from capacity constraints and competition, even as AI momentum and Azure growth drive demand beyond available supply.
Top Analyst Reports for Microsoft, Bank of America & Roche
Microsoft faces Azure capacity limits and rising competition, but AI momentum and Copilot adoption fuel cloud growth and enterprise demand.
Roche To Showcase Broad Ophthalmology Data Portfolio At ARVO 2026, Today
(RTTNews) - Roche (RHHBY) will present one of the largest ophthalmology data packages at this year's ARVO Annual Meeting, highlighting new real-world findings and clinical updates across its marketed ...
Where Roche Fits In A 2026 Portfolio
Roche (OTC: RHHBY) (OTC: RHHBF) (OTC: RHHVF) is not a story about rapid expansion in 2026. It is a story about resilience. In a European market where growth remains uneven, and investors are becomi...
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from ...
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Resear...
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced the launch of All Eyes on DME, a campaign developed in partnership with adv...
Roche CEO: Obesity drug pipeline could challenge market leaders
Thomas Schinecker, CEO at Roche discusses Q1 earnings, and explains the timeline behind the company's launch of their GLP-1 drug offering.
Europe risks falling further behind in medicine race, warns Roche CEO
Europe risks falling further behind the United States and China in pharmaceutical research and innovation because of "mind-blowing" bureaucracy and government policies threatening jobs, Roche Chief E...
Roche (RHHBY) Reports Q1 Sales Decline Amid Currency Challenges
Roche (RHHBY) Reports Q1 Sales Decline Amid Currency Challenges
Roche Reports Sales Decline Amid Strong Swiss Franc and Generic Competition
Roche Reports Sales Decline Amid Strong Swiss Franc and Generic Competition
Iran won't give up its “new nuclear weapon” - the Strait of Hormuz: David Roche
David Roche of Quantum Strategy warns of a 3% global economic decline as tankers halt movement through the Gulf and Red Sea. He further argues that markets are disconnected from reality, underestimati...
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Currency effects weighed on the Swiss drugmaker's first-quarter earnings
Roche Backs Full-Year View as Quarterly Sales Rise
Roche confirmed its full-year guidance after reporting a first-quarter rise in sales driven by high demand for its innovative medicines and diagnostics.
Roche Q1 sales down on forex effects
Swiss drugmaker Roche said on Thursday that its first-quarter sales declined because of negative foreign exchange effects but rose at constant exchange rates.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmac...
Roche's ENSPRYNG Cuts Relapse Risk In Rare Neurological Disease
(RTTNews) - Roche (RHHBY) yesterday announced new results from its Phase III METEOROID study showing that ENSPRYNG reduced the risk of relapse by 68% compared to placebo in patients with myelin oligod...
Genentech's Fenebrutinib Slashes Relapses By Over 50% In RMS , But Safety Signals Cast A Shadow
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), reported positive data for Fenebrutinib, its investigational candidate from the Phase 3, FENhance 1 and 2 studies in relapsing multiple scle...
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals while data released on Wednes...